Trading Members of the Exchange are hereby informed that effective from Monday, February 22, 2016 the Equity Shares of Ganga Pharmaceuticals Limited shall be listed and admitted to dealings on the SME Platform of Exchange in the list of ‘MT’ Group of Securities.
Name of the company
|
Securities
|
Market Lot
|
Scrip Code
|
Ganga Pharmaceuticals Limited
|
40,61,500 equity shares of Rs. 10/- each fully paid up
Distinctive Nos.
1 to 40,61,500
|
8,000 Shares
|
539680
|
1 - A, 802, N.G. Suncity Ph II,
Kandivali East,
Mumbai 400101,
Maharashtra, India
Tel No: +91 250 609 8333/444
Fax No: +91 250 2528602
Email: ayurvedganga@gmail.com
Website: www.ayurvedganga.com
|
Abbreviated name on bolt system
GANGAPHARM
|
Scrip ID on BOLT System
GANGAPHARM
|
ISIN No.
INE615T01017
|
Issue Price:
Rs. 15/- per share
|
Date of Allotment in the public issue:
February 17, 2016
|
1. Trading Members may note that as per the guidelines issued by SEBI dated 16th February, 2000, securities of the company will only be traded in Dematerialised form. Trades effected in this scrip will be in minimum market lot (i.e. 8,000 equity shares) and the same shall be modified by the Exchange from time to time by giving prior market notice of atleast one month.
2. The trading in the scrip shall continue to remain in Trade-for-Trade segment till further notice since 100% of promoter shareholding of the company is not in demat form, as per extent SEBI guidelines.
3. Trading Members are requested to note that the above security will be available for trading in continuous trading session.
4. Trading Members may note that the shares bearing the distinctive numbers, the details of which are attached as Annexure I, are not transferable till the date(s) mentioned against them and would not be a good delivery in the market till then. The company has informed the Exchange that in respect of shares in physical form, the respective share certificates have been enfaced with their non-transferability. The company has informed the Exchange that in respect of shares in demat form, necessary corporate action has been executed to have the lock-in period marked in the depository’s records.
5. A copy of shareholding pattern submitted by the company is enclosed as Annexure II.
6. The company’s financial year ending is March 31.
7. All shares are ranking pari-passu including dividend entitlement.
8. The Market Maker to the issue as mentioned in the prospectus is given below:
Alacrity Securities Limited
101, 1st Floor, Hari Dharshan,
B Wing, Bhogilal Fadia Road,
Kandivali (West),
Mumbai - 400 067
Tel: +91-22-28073882/28073982;
Fax: +91-22-28073967
E-mail: alacritysec@gmail.com
Website: www.alacritysec.com
SEBI Registration No.: INB010909837
9. The Registrar to the issue as mentioned in the prospectus is given below:
Karvy Computershare Private Limited
Karvy Selenium Tower B, Plot 31-32,
Gachibowli, Financial District,
Nanakramguda,
Hyderabad 500 032
Tel : + 91 40 6716 2222/ 1-800-3454001
Fax : +91 40 2343 1551
Website: www.karishma.karvy.com
E-mail: einward.ris@karvy.com
Investor Grievance e-mail: gangapharma.ipo@karvy.com
SEBI Registration: INR000000221
In case members require any clarifications on the subject matter of this notice, they may please contact any of the following:
a) At the company:
Mr. Mustafa Shabbir Badami,
Company Secretary &
Compliance Officer
|
Corporate Office Address:
Gangatat, Dhanvantary Marg,
Gopchar Pada, Virar (East),
Mumbai 401 303, India
Tel No: +91 250 609 8333/444
Fax No: +91 250 2528602
Email: ayurvedganga@gmail.com
Website: www.ayurvedganga.com
|
b) At the Exchange:
Rupal Khandelwal
Manager
|
Tel.: (91) 022 22728262
|
Bhushan Mokashi
Dy. General Manager
Friday, February 19, 2016 |